Table 2. Impact of A3F 231V haplotype on AIDS progression assessed by Cox proportional hazards regression model.

Population	Disease outcome	no. total/events	Adjustment	RH (95% CI)	P
European American	AIDS 1987	707/318	unadjusted	0.68 (0.54–0.87)	0.002
		707/318	adjusteda	0.71 (0.55–0.90)	0.006
	PCP	703/134	unadjusted	0.53 (0.37–0.76)	0.0005
Africa American	AIDS 1987	281/48	unadjusted	0.39 (0.12–1.31)	0.12
		281/48	adjustedb	0.34 (0.10–1.18)	0.09

Dominant genetic model (231V/V or V/I vs. I/I) was tested and was stratified by sex, age and cohort.

^a adjusted for covariates HLA homozygosity, HLA-C, HLA-B*57, HLA-B*35PX, HLA-B*27, CCR5-Δ32, CCR5-59029 and the first 2 eigenvalues

^b adjusted for covariates HLA homozygosity, HLA-B*57, HLA-B*35PX, HLA-B*27, and CCR5-59029.